These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. Nielsen EI; Khan DD; Cao S; Lustig U; Hughes D; Andersson DI; Friberg LE J Antimicrob Chemother; 2017 Nov; 72(11):3108-3116. PubMed ID: 28961946 [TBL] [Abstract][Full Text] [Related]
5. A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria. Kristoffersson AN; Bissantz C; Okujava R; Haldimann A; Walter I; Shi T; Zampaloni C; Nielsen EI J Antimicrob Chemother; 2020 Feb; 75(2):400-408. PubMed ID: 31670804 [TBL] [Abstract][Full Text] [Related]
6. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. Nielsen EI; Cars O; Friberg LE Antimicrob Agents Chemother; 2011 Apr; 55(4):1571-9. PubMed ID: 21282424 [TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin. Khan DD; Friberg LE; Nielsen EI J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Nielsen EI; Cars O; Friberg LE Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983 [TBL] [Abstract][Full Text] [Related]
9. Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Minichmayr IK; Kappetein S; Brill MJE; Friberg LE Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009905 [TBL] [Abstract][Full Text] [Related]
10. GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies - development and application in pediatric antibiotic studies. Gastine S; Rashed AN; Hsia Y; Jackson C; Barker CIS; Mathur S; Tomlin S; Lutsar I; Bielicki J; Standing JF; Sharland M Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1091-1098. PubMed ID: 31747323 [No Abstract] [Full Text] [Related]
11. Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic-Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Sou T; Kukavica-Ibrulj I; Levesque RC; Friberg LE; Bergström CAS Mol Pharm; 2020 May; 17(5):1458-1469. PubMed ID: 31951139 [TBL] [Abstract][Full Text] [Related]
12. Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data. Zhao C; Wistrand-Yuen P; Lagerbäck P; Tängdén T; Nielsen EI; Friberg LE Int J Antimicrob Agents; 2020 Jun; 55(6):105941. PubMed ID: 32171741 [TBL] [Abstract][Full Text] [Related]
13. Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond. Rao GG; Landersdorfer CB Int J Antimicrob Agents; 2021 Aug; 58(2):106368. PubMed ID: 34058336 [TBL] [Abstract][Full Text] [Related]
14. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents. Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351 [TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution. Witzany C; Rolff J; Regoes RR; Igler C Microbiology (Reading); 2023 Jul; 169(7):. PubMed ID: 37522891 [TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure. Ungphakorn W; Tängdén T; Sandegren L; Nielsen EI J Antimicrob Chemother; 2016 Sep; 71(9):2521-33. PubMed ID: 27330073 [TBL] [Abstract][Full Text] [Related]
17. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Standing JF Br J Clin Pharmacol; 2017 Feb; 83(2):247-254. PubMed ID: 27567102 [TBL] [Abstract][Full Text] [Related]
18. A New Pharmacokinetic-Pharmacodynamic Model To Characterize the Inoculum Effect of Acinetobacter baumannii on Polymyxin B Akrong G; Chauzy A; Aranzana-Climent V; Lacroix M; Deroche L; Prouvensier L; Buyck JM; Couet W; Marchand S Antimicrob Agents Chemother; 2022 Jan; 66(1):e0178921. PubMed ID: 34780268 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Barker CI; Germovsek E; Hoare RL; Lestner JM; Lewis J; Standing JF Adv Drug Deliv Rev; 2014 Jun; 73(100):127-39. PubMed ID: 24440429 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological indices in antibiotic therapy. Barger A; Fuhst C; Wiedemann B J Antimicrob Chemother; 2003 Dec; 52(6):893-8. PubMed ID: 14613960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]